ClinicalTrials.gg
RecruitingNCT05243290Updated Jul 24, 2025

Nicotinamide Riboside Clinical Trial for GWI

An interventional study of Nicotinamide Riboside and Placebo in Gulf War Illness, sponsored by Roskamp Institute Inc.. Recruiting at 2 sites in United States. Open to participants aged 47 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Roskamp Institute Inc. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
47 Years to 70 Years
Sex
All
01

Study summary

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Read the detailed description

The 1991 Gulf War (GW) was fought by a coalition of 30 countries that included 700,000 U.S. troops. Although the war itself lasted two months, adverse health consequences from this conflict are still experienced by GW veterans. Soon after their return, many soldiers started reporting multiple, seemingly unrelated symptoms, such as memory impairment, fatigue, gastrointestinal problems, and widespread pain. This illness, termed Gulf War Illness (GWI), affects about 32% of GW veterans. Several preclinical studies suggest the presence of bioenergetic deficits in the blood and brains of veterans with GWI, as well as in the mouse models of this illness. The investigators' recent work shows that plasma levels of bioenergetic metabolites, such as nicotinamide adenine dinucleotide (NAD+), are lower in veterans with GWI compared to healthy GW controls. This corresponds with low Sirt1 levels in the peripheral blood mononuclear cells (PBMC) from veterans with GWI. Given the importance of NAD+ in cellular bioenergetics, various approaches have been explored for supplementing NAD+. Among these, supplementation with the NAD+ precursor nicotinamide riboside (NR) appears to be a viable option, since this form of NAD+ can enter the cell and cross the blood-brain-barrier. The investigators' recent animal studies show that supplementation with NR, a member of the vitamin B3 family, can correct the bioenergetic deficits in GWI mice, which corresponds with an improvement in fatigue-type behavior that is commonly reported by veterans with GWI. The main objective of this project is to determine, through the use of metabolomics and biochemical assays, if NR supplementation can maintain a healthy bioenergetic profile in the blood of veterans with GWI. The secondary objective is to determine if NR can maintain healthy blood lipid and immune biomarker profiles in GWI veterans. The study will also explore whether NR can improve general health and well-being of veterans with GWI.

02

Conditions studied

  • Gulf War Illness
03

In context

Lead sponsor

Roskamp Institute Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
47 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes, all ethnic groups, and ages 47 to 70 years.
  • Subject willing and able to give .
  • Medically stable as per the investigator's discretion.
  • Negative urine pregnancy test for females of . A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is (no menstrual cycle for 2 years or more).
  • If female of childbearing potential, must be willing to use adequate during the study and for 30 days after the last dose. Females agreeing to take an acceptable form of birth control per investigator discretion (where relevant). Females must prevent pregnancy or otherwise be unable to conceive.
  • Veterans deployed to the Gulf War between August 1990 and August 1991.
  • Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
  • Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.).

Exclusion criteria

Exclusion Criteria:

  • Diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms, as per investigator discretion.
  • Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use .
  • Have , allergy, or sensitivity to NR, vitamin B3, or (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide).
  • Any significant medical condition that could interfere with study conduct, as per investigator discretion. These may include but are not limited to the following: untreated chronic hypertension (defined as systolic > 180 mmHg; diastolic >110 mmHg), myocardial infarction within 6 months of screening, renal failure, hepatic failure, and/or receiving chemotherapy.
  • lab values for clinical laboratory assessments, as per investigator discretion.
  • Poor venous access.
  • Current use of any NR supplement products (such as nicotinamide, nicotinamide mononucleotide (NMN), vitamin B3/Niacin, vitamin B complex, etc.) within 30 days of screening.
  • Participation in another clinical trial involving dietary or pharmaceutical intervention within 90 days of screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Study Supplement: NR

    26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.

    Dietary Supplement: Nicotinamide Riboside

  • Placebo comparator
    Control

    26 subjects will take the placebo during the first phase of the study (10 weeks).

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementNicotinamide-beta-ribosideStudies of Nicotinamide-beta-ribosideNicotinamide-beta-riboside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.

  • Dietary supplementPlacebo

    Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.

06

What researchers measure

Primary outcomes

  1. Changes in plasma NAD+ levels

    The primary objective is to determine if NR can increase plasma NAD+ levels in GWI veterans.

    Time frame: 10 weeks

Secondary outcomes

  1. Changes in lipid profiles

    The secondary objective is to determine if NR can help maintain healthy blood lipid in the blood of veterans with GWI.

    Time frame: 10 weeks

  2. Changes in immune biomarker profiles

    The secondary objective is to determine if NR can help maintain normal cytokine levels in the blood of veterans with GWI.

    Time frame: 10 weeks

Other outcomes

  1. Changes in fatigue

    The study will use the Multidimensional Fatigue Inventory (MFI-20) to assess fatigue.

    Time frame: 10 weeks

  2. Changes in memory (neurocognitive)

    The study will use the CNS Vital Signs computerized neurocognitive assessment software to assess memory. The computerized test uses individual tests to comprise a neurocognitive index score that can be used to evaluate neurocognitive status.

    Time frame: 10 weeks

  3. Changes in memory (neuropsychological)

    The study will use the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) cognitive test to assess memory. The test incorporates immediate memory, visuospatial/constructional, language, attention, and delayed memory components to determine a total scaled score for neuropsychological status. This total score ranges from 200 to 800, with higher scores increasing the associated percentile.

    Time frame: 10 weeks

  4. Changes in general well-being

    The study will use the Quality of Life Scale (SF36) to assess quality of life.

    Time frame: 10 weeks

  5. Changes in mood

    The study will use the Profile of Mood States (POMS) to assess mood.

    Time frame: 10 weeks

  6. Changes in pain

    The study will use the McGill Pain Questionnaire (SF-MPQ) to assess pain.

    Time frame: 10 weeks

07

Study locations

2 of 2 sites recruiting
  • Nova Southeastern University
    Fort Lauderdale, Florida 33314, United States
    Recruiting
    • Kamoly Dorneles · Contactkdornele@nova.edu · (954) 262-1343
    • Nancy Klimas, MD · Principal investigator
    • Amanpreet Cheema, PhD · Principal investigator
  • The Roskamp Institute
    Sarasota, Florida 34243, United States
    Recruiting
    • Dakota Helgager · Contactdhelgager@roskampclinic.org · 9412568019
    • Laila Abdullah, PhD · Principal investigator
    • Michael Hoffmann, MD · Principal investigator
08

References and documents

Publications

  • White RF, Steele L, O'Callaghan JP, Sullivan K, Binns JH, Golomb BA, Bloom FE, Bunker JA, Crawford F, Graves JC, Hardie A, Klimas N, Knox M, Meggs WJ, Melling J, Philbert MA, Grashow R. Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. Cortex. 2016 Jan;74:449-75. doi: 10.1016/j.cortex.2015.08.022. Epub 2015 Sep 25. PubMed 26493934 ↗
  • Spector R, Johanson CE. Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J Neurochem. 2007 Oct;103(2):425-38. doi: 10.1111/j.1471-4159.2007.04773.x. Epub 2007 Jul 20. PubMed 17645457 ↗
  • Joshi U, Evans JE, Pearson A, Saltiel N, Cseresznye A, Darcey T, Ojo J, Keegan AP, Oberlin S, Mouzon B, Paris D, Klimas N, Sullivan K, Mullan M, Crawford F, Abdullah L. Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. Neurotoxicology. 2020 Jul;79:84-94. doi: 10.1016/j.neuro.2020.04.006. Epub 2020 Apr 25. PubMed 32343995 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Apr 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 17, 2022
StartActual
Apr 13, 2022
Primary completionActual
Apr 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243290
Lead sponsor
Roskamp Institute Inc.
Collaborators
United States Department of Defense, Nova Southeastern University
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Apr 13, 2022
Primary completion
Apr 30, 2025
Completion
Dec 31, 2025 (estimated)
Last update
Jul 24, 2025

Study contacts

Dakota Helgager
Contact
dhelgager@roskampclinic.org
9412568019 ext. 3008
Laila Abdullah, PhD
principal investigator · The Roskamp Institute
Michael Hoffmann, MD
principal investigator · The Roskamp Institute
Nancy Klimas, MD
principal investigator · Nova Southeastern University
Amanpreet Cheema, PhD
principal investigator · Nova Southeastern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide-beta-riboside

Start the discussion